A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
Status:
Recruiting
Trial end date:
2028-05-09
Target enrollment:
Participant gender:
Summary
The purpose of this study to see how the brain absorbs, distributes, and gets rid of
tucatinib in people who have HER2+ cancers (breast cancer, NSCLC, CRC, or GEC) that have
spread to the brain, and to learn more about how cancer cells develop resistance to
treatment. The researchers will do research tests to look for genetic differences between
HER2+ breast cancer that has spread to the brain and progressed during treatment with
tucatinib and cancers that are being treated with tucatinib for the first time.